DaVita Inc. (NYSE:DVA) Shares Purchased by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC lifted its position in shares of DaVita Inc. (NYSE:DVA) by 17.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 259,906 shares of the company’s stock after purchasing an additional 37,899 shares during the period. Wedge Capital Management L L P NC owned about 0.32% of DaVita worth $39,758,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. UMB Bank n.a. boosted its position in shares of DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $29,000 after purchasing an additional 76 shares during the period. Copia Wealth Management acquired a new position in shares of DaVita during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. acquired a new position in DaVita during the fourth quarter worth $41,000. Coppell Advisory Solutions LLC lifted its stake in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after purchasing an additional 100 shares during the period. Finally, Canada Post Corp Registered Pension Plan acquired a new position in DaVita during the fourth quarter worth $55,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a report on Friday, February 21st. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Finally, Truist Financial decreased their price target on DaVita from $170.00 to $164.00 and set a “hold” rating for the company in a report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $164.50.

DaVita Trading Up 0.1%

DVA opened at $137.95 on Friday. The stock has a market capitalization of $10.41 billion, a PE ratio of 12.84, a P/E/G ratio of 1.07 and a beta of 1.11. The firm’s fifty day moving average price is $142.56 and its 200 day moving average price is $152.07. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 12-month low of $131.76 and a 12-month high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.22 billion. During the same period last year, the business posted $2.26 earnings per share. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. As a group, research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.